16.17  -0.06 (-0.37%)		08-18 16:00
Open: 16.36 High: 16.52 Volume: 6,607,700		Pre. Close: 16.23 Low: 16.17 Market Cap: 18,831(M)

Short term
Mid term
Targets	6-month :	20.35	1-year :	21.47
Resists	First :	17.43	Second :	18.38
Pivot price	16.81
Supports	First :	15.88	Second :	13.21
MAs	MA(5) :	16.15	MA(20) :	16.96
	MA(100) :	15.83	MA(250) :	13.33
MACD	MACD :	-0.2	Signal :	-0.1
%K %D	K(14,3) :	13.1	D(3) :	10.1
RSI	RSI(14): 40.3
52-week	High :	18.38	Low :	9.17

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ VTRS ] has closed above bottom band by 27.8%. Bollinger Bands are 58.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	16.55 - 16.65	16.65 - 16.75
Low:	15.91 - 16.01	16.01 - 16.12
Close:	15.97 - 16.15	16.15 - 16.35

Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.

Mon, 17 Aug 2026
Viatris Inc. (VTRS) Stock Analysis: Healthcare Giant with a 13.99% Upside and Strategic Collaborations - DirectorsTalk Interviews

Sat, 15 Aug 2026
5 Must-Read Analyst Questions From Viatris’s Q2 Earnings Call - Yahoo Finance

Fri, 14 Aug 2026
Viatris Stock Price Forecast. Should You Buy VTRS? - StockInvest.us

Thu, 13 Aug 2026
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine? - Yahoo Finance

Wed, 12 Aug 2026
Davis Selected Advisers (VTRS) discloses 75.2M-share, 6.5% stake in Viatris Inc - Stock Titan

Sun, 09 Aug 2026
Viatris (VTRS) Is Down 6.4% After Raising 2026 Guidance And Completing Major Buyback Program - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	1,150 (M)
Shares Float	1,140 (M)
Held by Insiders	0.3 (%)
Held by Institutions	89.8 (%)
Shares Short	47,220 (K)
Shares Short P.Month	45,050 (K)

EPS	-0.38
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	12.59
Profit Margin	-2.8 %
Operating Margin	12.5 %
Return on Assets (ttm)	2.6 %
Return on Equity (ttm)	-2.8 %
Qtrly Rev. Growth	4.9 %
Gross Profit (p.s.)	5.16
Sales Per Share	12.81
EBITDA (p.s.)	3.73
Qtrly Earnings Growth	0 %
Operating Cash Flow	2,330 (M)
Levered Free Cash Flow	2,680 (M)

PE Ratio	-43.71
PEG Ratio	1.1
Price to Book value	1.28
Price to Sales	1.26
Price to Cash Flow	7.98

Dividend	0.11
Forward Dividend	0
Dividend Yield	0.7%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.